Patent Assignment
Reel/Frame 067870/0874
Security Interest
Recorded: 2024-06-28
Pages: 11
Assignors
BRIDGEBIO PHARMA, INC.
Executed: 2024-06-18
EIDOS THERAPEUTICS, INC.
Executed: 2024-06-18
ML BIO SOLUTIONS INC.
Executed: 2024-06-18
NAVIRE PHARMA, INC.
Executed: 2024-06-18
FERRO THERAPUETICS, INC.
Executed: 2024-06-18
QED THERAPEUTICS, INC.
Executed: 2024-06-18
BRIDGEBIO GENE THERAPY RESEARCH, INC.
Executed: 2024-06-18
BRIDGEBIO SERVICES INC.
Executed: 2024-06-18
CANTERO THERAPEUTICS, INC.
Executed: 2024-06-18
Assignee
BLUE OWL CAPITAL CORPORATION
399 PARK AVENUE, 37TH FLOOR, NEW YORK, NEW YORK, 10022
Covered Properties
(11)
Combination Therapy Using Substituted Pyrimidin-4(3H)-Ones and Sotorasib
PCT:
PCT/US2022/045413 ↗
Processes for Preparing Ag-10, Its Intermediates, and Salts Thereof
Application:
18/413,175 →
Publication:
US 2024/0239751
Gene Therapy for Tuberous Sclerosis
Application:
18/570,040 →
Publication:
US 2024/0261439
Gene Therapy for Galactosemia
Application:
18/575,350 →
Publication:
US 2025/0001008
PTPN11 Inhibitors
Application:
18/587,790 →
Deuterated Infigratinib Compounds
Application:
18/599,623 →
Publication:
US 2025/0101002
Assays for Alpha-Dystroglycan Glycosylation and Methods for Using Same
Application:
18/605,744 →
Publication:
US 2024/0369576
Combination Therapy Using a PTPN11 Inhibitor and an Egfr Inhibitor
Application:
18/696,952 →
Publication:
US 2025/0195520
Substituted Pyrimidin-4(3H)-Ones for Use in Treating Cancer
Application:
18/698,694 →
Publication:
US 2025/0213563
1H-1,2,3-Triazole-4-Carboxylic Acids for Treatment of Hyperoxaluria and Kidney Stones
Application:
18/700,172 →
Publication:
US 2024/0423961
Methods and Compositions for Treating Leukodystrophies
Application:
18/700,508 →
Publication:
US 2026/0048146
Related Assignments
(7)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Jan 19, 2024
From: SCOTT, DAVID WAYNE
To: BRIDGEBIO GENE THERAPY RESEARCH, INC.
Reel/Frame 066181/0563 →
Assignment of Assignor's Interest
Apr 1, 2024
From: CHAND, POORAN; GUPTA, YOGESH KUMAR; KUMAWAT, RAKESH KUMAR; ALHAMADSHEH, MAMOUN
To: EIDOS THERAPEUTICS, INC.
Reel/Frame 066965/0001 →
Assignment of Assignor's Interest
May 3, 2024
From: BEARD, CLAYTON; CHAPMAN, JULIA NICOLE; MCCOY, DANIEL DAVID
To: BRIDGEBIO GENE THERAPY RESEARCH, INC.
Reel/Frame 067313/0466 →
Assignment of Assignor's Interest
Jun 4, 2024
From: LAFORET, GENEVIEVE; SHAYWITZ, ADAM; KIRBY, KATHLEEN M.
To: BRIDGEBIO SERVICES INC.
Reel/Frame 067608/0887 →
Assignment of Assignor's Interest
Jun 4, 2024
From: BRIDGEBIO SERVICES INC.
To: ASPA THERAPEUTICS, INC.
Reel/Frame 067608/0968 →
Assignment of Assignor's Interest
Jun 4, 2024
From: ASPA THERAPEUTICS, INC.
To: BRIDGEBIO GENE THERAPY LLC
Reel/Frame 067609/0031 →
Release of Security Interest in Patent Collateral
Mar 5, 2025
From: BLUE OWL CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
To: BRIDGEBIO PHARMA, INC.; QED THERAPEUTICS, INC.; EIDOS THERAPEUTICS, INC.; ML BIO SOLUTIONS INC.
Reel/Frame 070551/0120 →